Ainos Inks VELDONA License Deal Worth Up to $10M, Retains 25% Sublicensing Cut
AIMD sits 19% above its 52-week low of $1.26 on light trading volume (0.3× avg).
Summary
Ainos signed a VELDONA license agreement with BioPhoenix, establishing a collaboration framework with a potential aggregate value of $10 million. The deal covers two initial indications—Sjögren's disease and thrombocytopenia—with BioPhoenix funding and executing clinical and regulatory development. Ainos retains platform ownership, product supply opportunities, and a 25% share of net sublicensing revenue. The agreement includes a $600,000 upfront license fee due after technology transfer, a one-time first sublicense fee, and a 25% share of net sublicensing revenue. If all additional indications are licensed, total fees would be approximately $10.0 million. The $10 million is conditional and not guaranteed, but the structure reduces Ainos' need to independently fund late-stage development. This follows the company's Q2 loss of $4.6 million and going concern warning, making the partner-funded model a meaningful capital relief.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 8-K discloses a $600,000 upfront license fee due after technology transfer, a one-time first sublicense fee, and a 25% share of net sublicensing revenue. If all additional indications are licensed, total fees would be approximately $10.0 million.
At the time of this announcement, AIMD was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $1.26 to $4.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.